专利号:US-12383499-B2 优先权日:2018-01-01 标题:Scale up synthesis of silicasome nanocarriers 发明人:NEL ANDRE E; MENG HUAN; LIU XIANGSHENG 权利人:UNIV CALIFORNIA 摘要:In order to facilitate the approval and commercialization of silicasome drug delivery systems (e.g. irinotecan silicasomes) it is necessary to scale up synthesis of the drug-loaded silicasomes. In this regard, it was discovered that the synthesis protocols used for laboratory synthesis of drug-loaded silicasomes (e.g., 500 mg/batch) do not scale to large scale silicasome production, because the resulting products were too heterogeneous for use as pharmaceuticals. Accordingly, new methods are provided herein that effectively afford the large-scale production of mesoporous silica nanoparticles (MSNPs) and lipid bilayer coated MSNPs (silicasomes).
专利号:US-2022118094-A1 优先权日:2019-02-21 标题:Synthesis of biomimetic cell wall structure 发明人:WANG YONG; SHI PENG 权利人:PENN STATE RES FOUND 摘要:The present invention relates generally to methods of generating a biomimetic cell wall (BCW) on a target surface, compositions comprising the BCW, and methods of use of the compositions, including biomedical applications of the BCW coated compositions.
专利号:WO-2012032531-A1 优先权日:2010-09-06 标 题:Process for the manufacture of irinotecan hydrochloride by total synthesis 发明人:ALLA VENKATA RAMA RAO; RAO RAMAKRISHNA; RAMARAO CHANDRASHEKAR; NANDIPATI RAMADEVI; CHAMLE VINAY AVINASH 权利人:AVRA LAB PVT LTD; ALLA VENKATA RAMA RAO; RAO RAMAKRISHNA; RAMARAO CHANDRASHEKAR; NANDIPATI RAMADEVI; CHAMLE VINAY AVINASH 摘要:Disclosed herein is a highly safe and easily scalable process for the production of 7-Ethyl- 10-hydroxycamptothecin and its conversion to Irinotecan hydrochloride by total synthesis.
专利号:EP-3735250-A1 优先权日:2018-01-01 标题:Scale up synthesis of silicasome nanocarriers
专利号:US-2019216736-A1 优先权日:2018-01-01 标题:Scale up synthesis of silicasome nanocarriers
专利号:JP-2008505893-A 优先权日:2004-07-07 标题:Synthesis of Minus Beta Element, Minus Beta Elemental, Minus Beta Elementenol, Minus Beta Fluorinated Elementene and Their Analogues, Intermediates and Drugs
1: Schwartzman AD, Sethi R, Smith R. Multiorgan failure in a patient treated with the 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan regimen. Clin Colorectal Cancer. 2013 Jun;12(2):136-9. doi: 10.1016/j.clcc.2012.09.005. Epub 2012 Oct 24. Review. Review. doi: 10.1002/ijc.27775. Epub 2012 Sep 1. Review. doi: 10.1016/j.nec.2012.01.005. Epub 2012 Feb 18. Review. Review. Review. Review. doi: 10.1517/14656566.2011.566558. Epub 2011 Mar 9. Review. doi: 10.1097/CAD.0b013e3283425c14. Review. doi: 10.1159/000314993. Epub 2010 Nov 22. Review. doi: 10.3816/CCC.2010.n.036. Review. doi: 10.3109/07357907.2010.483499. Epub 2010 Sep 27. Review. doi: 10.1097/CAD.0b013e32833c57cf. Review. doi: 10.2217/pgs.10.95. Review. 15: Xu T, Chen J, Lu Y, Wolff JE. Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis. BMC Cancer. 2010 Jun 2;10:252. doi: 10.1186/1471-2407-10-252. Review. 16: Fujita K, Sparreboom A. Pharmacogenetics of irinotecan disposition and toxicity: a review. Curr Clin Pharmacol. 2010 Aug;5(3):209-17. Review. doi: 10.1586/era.09.179. Review. doi: 10.1097/COC.0b013e3181d27361. Review. doi: 10.1016/j.ejca.2010.02.049. Epub 2010 Mar 23. Review. doi: 10.2217/pgs.10.19. Review.
合成参考文献
参考文献:10.1007/s13346-018-0527-3 摘要:Kulkarni P, Rajadurai M, Sevilimedu A, Basaveni S, Yellanki S, Medishetti R, Saxena U. Magnetic nanoparticle formulation for targeted delivery of chemotherapeutic irinotecan to lungs. Drug Delivery and Translational Research. 2018 May 01;8(5):1450–9. doi: 10.1007/s13346-018-0527-3.